CSL Seqirus mini oral: Guideline-driven iron therapy in Heart Failure: what every cardiologist should know
| Friday, August 15, 2025 |
| 3:15 PM - 3:45 PM |
| Theatrette 4 |
Details
Iron deficiency (ID) is a prevalent and modifiable comorbidity in heart failure (HF), affecting up to 50% of patients and contributing to reduced functional capacity, increased hospitalizations, and poorer quality of life. Despite its burden, ID remains underdiagnosed and undertreated. Intravenous (IV) iron therapy is now a guideline-recommended standard of care, offering a clinically proven and economically valuable solution for improving outcomes in HF.
This presentation equips cardiologists with the latest evidence, diagnostic criteria, and practical strategies to integrate IV iron therapy into routine HF management.
Speaker
Prof Andrew Sindone
Director of The Heart Failure Unit And Department of Cardiac Rehabilitation
Concord Hospital
Guideline-driven Iron Therapy in Heart Failure: What every cardiologist should know
3:15 PM - 3:45 PMBiography
Prof Andrew Sindone B. Med (hons), MD, FRACP, FCSANZ, FNHFA is Director of the Heart Failure Unit and Department of Cardiac Rehabilitation at Concord Hospital and Head of Department of Cardiology at Ryde Hospital. He runs the Concord Hospital Heart Failure Clinic, research, rehabilitation and outreach programs. He has been Principal Investigator in 50 international, multi-centre, clinical trials and authored over 100 articles. He is a Co-Chairman of the NSW Cardiovascular Expert Reference Group, Fellow of the Heart Foundation of Australia and is co-author of the Australian and the Asia Pacific Heart Failure Guidelines.
